An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)

Abroad (travel likely)RecruitingPHASE2

Conditions

Myotonic Dystrophy 1

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Calgary, Calgary, Alberta, Canada
Contact: Study coordinator (Patient Advocacy) · clinicaltrials@pepgen.com · 781-797-0979
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Contact: Study coordinator (Patient Advocacy) · clinicaltrials@pepgen.com
CIUSSS du Saguenay-Lac-Saint-Jean, Saguenay, Canada
Contact: Study coordinator (Patient Advocacy) · clinicaltrials@pepgen.com

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1

Myotonic Dystrophy 1

Abroad (travel likely)RecruitingPHASE2

Calgary, Canada · Ottawa, Canada

Study of ATX-01 in Participants With DM1

Myotonic Dystrophy 1

Abroad (travel likely)RecruitingPHASE1, PHASE2

Los Angeles, United States · Gainesville, United States

Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy

Myotonic Dystrophy 1

Abroad (travel likely)RecruitingPHASE1, PHASE2

Liverpool, Australia · Birtinya, Australia

Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

Myotonic Dystrophy Type 1 (DM1) · DM1 · Myotonic Dystrophy

Abroad (travel likely)RecruitingPHASE3

La Jolla, United States · Atlanta, United States